

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Turner et al.

Application No.: 09/658,283

Group Art Unit: 1646

Filed: 09/08/00

Examiner: to be assigned

Title: Novel Human 7TM Proteins and Receptors  
and Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0041-USA

**RESPONSE TO NOTICE TO COMPLY WITH  
REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed December 14, 2001, in connection with the above-identified application, Applicants submit herewith: (i) a Sequence Listing in computer readable form pursuant to 37 C.F.R. § 1.821 (e); and (ii) a Verified Statement Concerning Sequence Listing Under 37 C.F.R. § 1.821(f). Applicants respectfully request the entry of the computer readable form of the Sequence Listing into the file.

Applicants believe that no fee in addition to the extension fee is due in connection with this response. However, the Commissioner is authorized to charge any additionally required fee to Deposit Account No. 50-0892.


Respectfully submitted,

January 14, 2002  
Date

*Lance K. Ishimoto by David W. Sheller* *DAVID W. SHELTER*  
Lance K. Ishimoto Reg. No. 41,866

Reg. No. 41,866

LEXICON GENETICS INCORPORATED  
4000 Research Forest Drive  
The Woodlands, TX 77381  
(281) 863-3333



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Turner et al.

Application No.: 09/658,283

Filed: 09/08/00

Group Art Unit:  
1646

Title: Novel Human 7TM Proteins and  
Receptors and Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0041-USA

RECEIVED  
FEB 07 2002  
TECH CENTER 1600/2900

**VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Drenda D. Thomas, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. § 1.821 - 1.825 in connection with the above-captioned patent application.
2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same, and that the computer readable form being submitted herewith does not include new matter.

January 14, 2002  
Date

Drenda D. Thomas



Application No.: 09/16823

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: \_\_\_\_\_

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**